Effect of Rosuvastatin 2.5 mg on Achieving Lipid Goals Defined by the 2007 Japan Atherosclerosis Society Guidelines / Journal of Rural Medicine
Journal of Rural Medicine
;
: 10-14, 2007.
Artigo
em Japonês
| WPRIM
| ID: wpr-361320
ABSTRACT
Objective:
The aim of the study was to assess the effect of rosuvastatin 2.5 mg, an inhibitor of HMG-CoA reductase, on achieving lipid goals defined by the 2007 Japan Atherosclerosis Society guidelines. Subjects andMethods:
Thirty-seven patients with moderate to high risk hypercholesterolemia (Mean age 64.8 ± 8.4) were treated with 2.5 mg/day of rosuvastatin and their lipid and hepatic function parameters were measured at the baseline and at Weeks 4 and 8.Results:
At 4 and 8 weeks after start of treatment, 74.1% and 92.6% of moderate risk patients, as well as 70% and 80% of high risk patients, achieved their LDL-C goals, respectively. In both moderate and high risk patients, the mean LDL-C/HDL-C ratio, which is considered as a prospective index for plaque regression, was significantly reduced (p<0.001 for both the moderate and high risk groups), and the mean LDL-C/HDL-C ratio decreased to less than 2 in moderate risk patients. No abnormal changes were observed in hepatic function tests during the study.Conclusion:
More than 80% of moderate to high risk patients with hypercholesterolemia achieved their lipid goals and the mean LDL-C/HDL-C ratio was significantly reduced after the 8-week short treatment of rosuvastatin 2.5 mg, suggesting the clinical possibility of continuous use of rosuvastatin for plaque regression.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Risco
/
Lipídeos
Tipo de estudo:
Estudo de etiologia
/
Guia de Prática Clínica
/
Fatores de risco
Idioma:
Japonês
Revista:
Journal of Rural Medicine
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS